Improved Outcomes of Thermal Ablation for Colorectal Liver Metastases: A 10-Year Analysis from the Prospective Amsterdam CORE Registry (AmCORE).
Colorectal liver metastases (CRLM)
Local tumor progression-free survival (LTPFS)
Long-term oncological outcomes
Microwave ablation (MWA)
Radiofrequency ablation (RFA)
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
14
12
2021
accepted:
09
04
2022
pubmed:
19
5
2022
medline:
27
7
2022
entrez:
18
5
2022
Statut:
ppublish
Résumé
To analyze long-term oncological outcomes of open and percutaneous thermal ablation in the treatment of patients with colorectal liver metastases (CRLM). This assessment from a prospective, longitudinal tumor registry included 329 patients who underwent 541 procedures for 1350 CRLM from January 2010 to February 2021. Three cohorts were formed: 2010-2013 (129 procedures [53 percutaneous]), 2014-2017 (206 procedures [121 percutaneous]) and 2018-2021 (206 procedures [135 percutaneous]). Local tumor progression-free survival (LTPFS) and overall survival (OS) data were estimated using the Kaplan-Meier method. Potential confounding factors were analyzed with uni- and multivariable Cox regression analyses. LTPFS improved significantly over time for percutaneous ablations (2-year LTPFS 37.7% vs. 69.0% vs. 86.3%, respectively, P < .0001), while LTPFS for open ablations remained reasonably stable (2-year LTPFS 87.1% [2010-2013], vs. 92.7% [2014-2017] vs. 90.2% [2018-2021], P = .12). In the latter cohort (2018-2021), the open approach was no longer superior regarding LTPFS (P = .125). No differences between the three cohorts were found regarding OS (P = .088), length of hospital stay (open approach, P = .065; percutaneous approach, P = .054), and rate and severity of complications (P = .404). The rate and severity of complications favored the percutaneous approach in all three cohorts (P = .002). Over the last 10 years efficacy of percutaneous ablations has improved remarkably for the treatment of CRLM. Oncological outcomes seem to have reached results following open ablation. Given its minimal invasive character and shorter length of hospital stay, whenever feasible, percutaneous procedures may be favored over an open approach.
Sections du résumé
BACKGROUND
BACKGROUND
To analyze long-term oncological outcomes of open and percutaneous thermal ablation in the treatment of patients with colorectal liver metastases (CRLM).
METHODS
METHODS
This assessment from a prospective, longitudinal tumor registry included 329 patients who underwent 541 procedures for 1350 CRLM from January 2010 to February 2021. Three cohorts were formed: 2010-2013 (129 procedures [53 percutaneous]), 2014-2017 (206 procedures [121 percutaneous]) and 2018-2021 (206 procedures [135 percutaneous]). Local tumor progression-free survival (LTPFS) and overall survival (OS) data were estimated using the Kaplan-Meier method. Potential confounding factors were analyzed with uni- and multivariable Cox regression analyses.
RESULTS
RESULTS
LTPFS improved significantly over time for percutaneous ablations (2-year LTPFS 37.7% vs. 69.0% vs. 86.3%, respectively, P < .0001), while LTPFS for open ablations remained reasonably stable (2-year LTPFS 87.1% [2010-2013], vs. 92.7% [2014-2017] vs. 90.2% [2018-2021], P = .12). In the latter cohort (2018-2021), the open approach was no longer superior regarding LTPFS (P = .125). No differences between the three cohorts were found regarding OS (P = .088), length of hospital stay (open approach, P = .065; percutaneous approach, P = .054), and rate and severity of complications (P = .404). The rate and severity of complications favored the percutaneous approach in all three cohorts (P = .002).
CONCLUSION
CONCLUSIONS
Over the last 10 years efficacy of percutaneous ablations has improved remarkably for the treatment of CRLM. Oncological outcomes seem to have reached results following open ablation. Given its minimal invasive character and shorter length of hospital stay, whenever feasible, percutaneous procedures may be favored over an open approach.
Identifiants
pubmed: 35585138
doi: 10.1007/s00270-022-03152-9
pii: 10.1007/s00270-022-03152-9
pmc: PMC9307533
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1074-1089Informations de copyright
© 2022. The Author(s).
Références
Meijerink MR, Puijk RS, van Tilborg A, et al. Radiofrequency and microwave ablation compared to systemic chemotherapy and to partial hepatectomy in the treatment of colorectal liver metastases: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2018;41:1189–204.
pubmed: 29666906
pmcid: 6021475
doi: 10.1007/s00270-018-1959-3
Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update. Radiology. 2014;273:241–60.
pubmed: 24927329
doi: 10.1148/radiol.14132958
Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol. 2010;33:11–7.
pubmed: 19924474
doi: 10.1007/s00270-009-9736-y
Gillams A, Goldberg N, Ahmed M, et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontiers meeting 2013. Eur Radiol. 2015;25:3438–54.
pubmed: 25994193
pmcid: 4636513
doi: 10.1007/s00330-015-3779-z
Bala MM, Riemsma RP, Wolff R, et al. Microwave coagulation for liver metastases. Cochrane Database Syst Rev. 2013;1:010163.
Puijk RS, Ruarus AH, Scheffer HJ, et al. Percutaneous liver tumour ablation: image guidance, endpoint assessment, and quality control. Can Assoc Radiol J. 2018;69:51–62.
pubmed: 29458955
doi: 10.1016/j.carj.2017.11.001
de Baere T, Tselikas L, Yevich S, et al. The role of image-guided therapy in the management of colorectal cancer metastatic disease. Eur J Cancer. 2017;75:231–42.
pubmed: 28237869
doi: 10.1016/j.ejca.2017.01.010
Salhab M, Canelo R. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther. 2011;7:463–75.
pubmed: 22269411
doi: 10.4103/0973-1482.92023
Nielsen K, van Tilborg AA, Meijerink MR, et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg. 2013;37:1340–7.
pubmed: 23494086
doi: 10.1007/s00268-013-1997-6
Vasiniotis Kamarinos N, Kaye EA, Sofocleous CT. Image-guided thermal ablation for colorectal liver metastases. Tech Vasc Interv Radiol. 2020;23: 100672.
pubmed: 32591188
doi: 10.1016/j.tvir.2020.100672
Giglio MC, Logghe B, Garofalo E, et al. Laparoscopic versus open thermal ablation of colorectal liver metastases: a propensity score-based analysis of local control of the ablated tumors. Ann Surg Oncol. 2020;27:2730.
doi: 10.1245/s10434-020-08243-w
Santambrogio R, Bianchi P, Pasta A, et al. Ultrasound-guided interventional procedures of the liver during laparoscopy: technical considerations. Surg Endosc. 2002;16:349–54.
pubmed: 11967695
doi: 10.1007/s004640090082
Takahashi H, Berber E. Role of thermal ablation in the management of colorectal liver metastasis. Hepatobiliary Surg Nutr. 2020;9:49–58.
pubmed: 32140478
pmcid: 7026789
doi: 10.21037/hbsn.2019.06.08
Shady W, Petre EN, Gonen M, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes–a 10-year experience at a single center. Radiology. 2016;278:601–11.
pubmed: 26267832
doi: 10.1148/radiol.2015142489
Elias D, De Baere T, Smayra T, et al. Percutaneous radiofrequency thermoablation as an alternative to surgery for treatment of liver tumour recurrence after hepatectomy. Br J Surg. 2002;89:752–6.
pubmed: 12027986
doi: 10.1046/j.1365-2168.2002.02081.x
Sofocleous CT, Petre EN, Gonen M, et al. CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. J Vasc Interv Radiol. 2011;22:755–61.
pubmed: 21514841
pmcid: 3120046
doi: 10.1016/j.jvir.2011.01.451
Livraghi T, Solbiati L, Meloni F, et al. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the “test-of-time approach.” Cancer. 2003;97:3027–35.
pubmed: 12784338
doi: 10.1002/cncr.11426
Nieuwenhuizen S, Puijk RS, van den Bemd B, et al. Resectability and ablatability criteria for the treatment of liver only colorectal metastases: multidisciplinary consensus document from the COLLISION Trial Group. Cancers (Basel). 2020;12:1779.
doi: 10.3390/cancers12071779
Solbiati L, Ahmed M, Cova L, et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology. 2012;265:958–68.
pubmed: 23091175
doi: 10.1148/radiol.12111851
Shi Y, Wang Z, Chi J, et al. Long-term results of percutaneous microwave ablation for colorectal liver metastases. HPB (Oxford). 2021;23:37–45.
doi: 10.1016/j.hpb.2020.04.007
Puijk RS, Des Plantes VZ, Nieuwenhuizen S, et al. Propofol compared to midazolam sedation and to general anesthesia for percutaneous microwave ablation in patients with hepatic malignancies: a single-center comparative analysis of three historical cohorts. Cardiovasc Intervent Radiol. 2019;42:1579–2068.
doi: 10.1007/s00270-019-02273-y
Puijk RS, Nieuwenhuizen S, van den Bemd BAT, et al. Transcatheter CT hepatic arteriography compared with conventional CT fluoroscopy guidance in percutaneous thermal ablation to treat colorectal liver metastases: a single-center comparative analysis of 2 historical cohorts. J Vasc Interv Radiol. 2020;31:1772–83.
pubmed: 32981819
doi: 10.1016/j.jvir.2020.05.011
Solbiati M, Muglia R, Goldberg SN, et al. A novel software platform for volumetric assessment of ablation completeness. Int J Hyperthermia. 2019;36:337–43.
pubmed: 30729818
doi: 10.1080/02656736.2019.1569267
Kaye EA, Cornelis FH, Petre EN, et al. Volumetric 3D assessment of ablation zones after thermal ablation of colorectal liver metastases to improve prediction of local tumor progression. Eur Radiol. 2019;29:2698–705.
pubmed: 30402706
doi: 10.1007/s00330-018-5809-0
Laimer G, Schullian P, Bale R. Stereotactic thermal ablation of liver tumors: 3D planning, multiple needle approach, and intraprocedural image fusion are the key to success-a narrative review. Biology (Basel). 2021;10:644.
Laimer G, Jaschke N, Schullian P, et al. Volumetric assessment of the periablational safety margin after thermal ablation of colorectal liver metastases. Eur Radiol. 2021;31:6489–99.
pubmed: 33447860
pmcid: 8379110
doi: 10.1007/s00330-020-07579-x
Puijk RS, Ahmed M, Adam A, et al. Consensus guidelines for the definition of time-to-event end points in image-guided tumor ablation: results of the SIO and DATECAN initiative. Radiology. 2021;301:533.
pubmed: 34581627
doi: 10.1148/radiol.2021203715
Vietti Violi N, Duran R, Demartines N, et al. Local recurrence rate in patients with colorectal cancer liver metastasis after wedge resection or percutaneous radiofrequency ablation. Int J Hyperthermia. 2018;34:1020–8.
pubmed: 29506424
doi: 10.1080/02656736.2017.1372644
Yu J, Liang P, Yu XL, et al. Local tumour progression after ultrasound-guided microwave ablation of liver malignancies: risk factors analysis of 2529 tumours. Eur Radiol. 2015;25:1119–26.
pubmed: 25407661
doi: 10.1007/s00330-014-3483-4
Wong J, Lee KF, Yu SC, et al. Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long-term results. HPB (Oxford). 2013;15:595–601.
doi: 10.1111/hpb.12014
Shady W, Petre EN, Do KG, et al. Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control. J Vasc Interv Radiol. 2018;29:268–75.
pubmed: 29203394
doi: 10.1016/j.jvir.2017.08.021
Elias D, Baton O, Sideris L, et al. Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections. Ann Surg Oncol. 2004;11:500–5.
pubmed: 15078636
doi: 10.1245/ASO.2004.08.019
Hamada A, Yamakado K, Nakatsuka A, et al. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol. 2012;30:567–74.
pubmed: 22664831
doi: 10.1007/s11604-012-0089-0
Tsitskari M, Filippiadis D, Zavridis P, et al. Efficacy and safety of percutaneous computed tomography-guided microwave ablation for colorectal cancer, oligometastatic liver-only disease: a single center’s experience. Ann Gastroenterol. 2021;34:61–7.
pubmed: 33414623
Faitot F, Faron M, Adam R, et al. Two-stage hepatectomy versus 1-stage resection combined with radiofrequency for bilobar colorectal metastases: a case-matched analysis of surgical and oncological outcomes. Ann Surg. 2014;260:822–7 (discussion 827-828).
pubmed: 25379853
doi: 10.1097/SLA.0000000000000976
Tinguely P, Dal G, Bottai M, et al. Microwave ablation versus resection for colorectal cancer liver metastases - a propensity score analysis from a population-based nationwide registry. Eur J Surg Oncol. 2020;46:476–85.
pubmed: 31837931
doi: 10.1016/j.ejso.2019.12.002
Hof J, Wertenbroek MW, Peeters PM, et al. Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases. Br J Surg. 2016;103:1055–62.
pubmed: 27193207
doi: 10.1002/bjs.10162
Imai K, Allard MA, Castro Benitez C, et al. Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases. Br J Surg. 2017;104:570–9.
pubmed: 28112813
doi: 10.1002/bjs.10447
Karanicolas PJ, Jarnagin WR, Gonen M, et al. Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg. 2013;148:597–601.
pubmed: 23699996
pmcid: 4089883
doi: 10.1001/jamasurg.2013.1431
Snyder RA, Hao S, Irish W, et al. Thirty-day morbidity after simultaneous resection of colorectal cancer and colorectal liver metastasis: American College of Surgeons NSQIP Analysis. J Am Coll Surg. 2020;230:617–27.
pubmed: 32007534
doi: 10.1016/j.jamcollsurg.2019.12.018
Comprehensive Cancer Organisation the Netherlands (I.K.N.L.). National evidence-based guideline. Colorectaalcarcinoom. https://richtlijnendatabase.nl/richtlijn/colorectaal_carcinoom_crc/startpagina_-_crc.html , Nov 2019. Accessed November 10, 2021
Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 and 5.0 [Internet]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm , Accessed November 10, 2021
IBM Corp. Released 2013. IBM® SPSS® Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.
(2019) RCT: R: A language and environment for statistical computing. R for Windows version 4.0.3. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/ .
STROBE Statement - Checklist of items that should be included in reports of cohort studies. Version 4. Oct/Nov 2007. ISPM - University of Bern 2009. www.strobe-statement.org . Accessed 10 Nov 2021.
Eltawil KM, Boame N, Mimeault R, et al. Patterns of recurrence following selective intraoperative radiofrequency ablation as an adjunct to hepatic resection for colorectal liver metastases. J Surg Oncol. 2014;110:734–8.
pubmed: 24965163
doi: 10.1002/jso.23689
Calandri M, Yamashita S, Gazzera C, et al. Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. Eur Radiol. 2018;28:2727–34.
pubmed: 29417253
doi: 10.1007/s00330-017-5273-2
Schiesser M, Chen JW, Maddern GJ, et al. Perioperative morbidity affects long-term survival in patients following liver resection for colorectal metastases. J Gastrointest Surg. 2008;12:1054–60.
pubmed: 18085344
doi: 10.1007/s11605-007-0438-y
Are C, Gonen M, Zazzali K, et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg. 2007;246:295–300.
pubmed: 17667509
pmcid: 1933562
doi: 10.1097/SLA.0b013e31811ea962
Hamady ZZ, Lodge JP, Welsh FK, et al. One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach. Ann Surg. 2014;259:543–8.
pubmed: 23732261
doi: 10.1097/SLA.0b013e3182902b6e
de Haas RJ, Wicherts DA, Flores E, et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008;248:626–37.
pubmed: 18936576
doi: 10.1097/SLA.0b013e31818a07f1
Sadot E, Koerkamp BG, Leal JN, et al. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg. 2015;262:476–85.
pubmed: 26258316
doi: 10.1097/SLA.0000000000001427
Davidson B, Gurusamy K, Corrigan N, et al. Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT. Health Technol Assess. 2020;24(21):1–38.
pubmed: 32370822
pmcid: 7232132
doi: 10.3310/hta24210
Puijk RS, Ruarus AH, Vroomen L, et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer. 2018;18:821.
pubmed: 30111304
pmcid: 6094448
doi: 10.1186/s12885-018-4716-8
Meijerink MR, Puijk RS, van den Tol MP, Dijkstra M, et al. COLLISION trial interim results: surgery vs. MWA. https://library.cirse.org/speakers/53812 . Presented at the CIRSE 2021 Summit, Virtual, Sept 25–29, 2021
Nieuwenhuizen S, Dijkstra M, Puijk RS, et al. Thermal ablation versus stereotactic ablative body radiotherapy to treat unresectable colorectal liver metastases: a comparative analysis from the prospective Amsterdam CORE Registry. Cancers. 2021;13:1.
doi: 10.3390/cancers13174303
Laimer G, Schullian P, Jaschke N, et al. Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation. Eur Radiol. 2020;30:2463.
pubmed: 32002642
pmcid: 7160081
doi: 10.1007/s00330-019-06609-7
Wright AS, Lee FT Jr, Mahvi DM. Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. Ann Surg Oncol. 2003;10:275–83.
pubmed: 12679313
doi: 10.1245/ASO.2003.03.045
Puijk RS, des Plantes VZ, Nieuwenhuizen S, et al. Propofol compared to midazolam sedation and to general anesthesia for percutaneous microwave ablation in patients with hepatic malignancies: a single-center comparative analysis of three historical cohorts. Cardiovasc Intervent Radiol. 2019;42:1597–608.
pubmed: 31243542
pmcid: 6775535
doi: 10.1007/s00270-019-02273-y
Alonzo M, Bos A, Bennett S, et al. The emprint ablation system with thermosphere technology: one of the newer next-generation microwave ablation technologies. Semin Intervent Radiol. 2015;32:335–8.
pubmed: 26622094
pmcid: 4640908
doi: 10.1055/s-0035-1564811
Radosevic A, Quesada R, Serlavos C, et al. Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial. Sci Rep. 2022;12:316.
pubmed: 35013377
pmcid: 8748896
doi: 10.1038/s41598-021-03802-x
Odisio BC, Yamashita S, Huang SY, et al. Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg. 2017;104:760–8.
pubmed: 28240361
pmcid: 5391264
doi: 10.1002/bjs.10490
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–15.
pubmed: 24120480
doi: 10.1016/S1470-2045(13)70447-9
Kanemitsu Y, Kato T, Shimizu Y, et al. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol. 2009;39:406–9.
pubmed: 19389795
doi: 10.1093/jjco/hyp035